Puma Biotechnology Inc PBYI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
-
Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology Reports Second Quarter 2026 Financial Results
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results
Trading Information
- Previous Close Price
- $9.84
- Day Range
- $9.50–10.00
- 52-Week Range
- $4.58–10.10
- Bid/Ask
- $9.00 / $9.45
- Shares Outstanding
- 51.62M
- Market Cap
- $490.91M
- Volume/Avg
- 454,881 / 328,064
Key Statistics
- Price/Earnings (Normalized)
- 15.12
- Price/Sales
- 2.20
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 179
Valuation
|
Metric
|
PBYI
|
|---|---|
Price/Earnings (Normalized) | 15.12 |
Price/Book Value | 3.63 |
Price/Sales | 2.20 |
Price/Cash Flow | 10.76 |
Price/Earnings
PBYI
Financial Strength
|
Metric
|
PBYI
|
|---|---|
Quick Ratio | 2.57 |
Current Ratio | 2.91 |
Interest Coverage | 8.76 |
Quick Ratio
PBYI
Profitability
|
Metric
|
PBYI
|
|---|---|
Return on Assets (Normalized) | 16.97% |
Return on Equity (Normalized) | 27.47% |
Return on Invested Capital (Normalized) | 22.22% |
Return on Assets
PBYI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|yLG!Gp^ | LOCK|m^?@z | $128B | |||
| Moderna Inc
MRNA
| LOCK|?TYg%n | LOCK|wWP | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@Y^Rsv | LOCK|>?%<# | $76B | |||
| argenx SE ADR
ARGX
| LOCK|!Bgl#^@ | LOCK|LZC | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!BDWWRC | LOCK|#B | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|vJ<<&V | LOCK|Q>vs? | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|yJFhxKp | LOCK|zl%? | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|!z>dvJb | LOCK|FP | $24B | |||
| Incyte Corp
INCY
| LOCK|YqBCW?@ | LOCK|&> | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|H#?Mnx | LOCK|&#B | $15B |
United States